RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
August 20, 2026
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Radiopharm Theranostics Receives Positive Recommendation from Data
Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202
Phase 1 HEAT Clinical Trial
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid
tumors
Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated
clinical proof-of-concept with positive safety and biodistribution
Sydney, Australia – 20 August 2026 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX,
“Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on
developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
announced that it has received a positive recommendation from the Data Safety and Monitoring
Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to
the next dose level of 180mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal
Growth Factor Receptor 2 (HER2)-positive advanced solid tumors1
. The DSMC is a multidisciplinary
committee that conducts detailed reviews of study data, discusses potential safety events and
provides recommendations regarding trial continuation.
“Advancing RAD202 into Cohort 4 marks a significant step forward in the development of one of our
most promising therapeutic candidates,” said Riccardo Canevari, CEO and Managing Director of
Radiopharm Theranostics. “The DSMC’s recommendation supports the favorable safety profile
observed to date and allows us to continue evaluating higher dose levels in patients with HER2-
positive advanced solid tumors. As we execute on our clinical development strategy, we remain
focused on unlocking the full potential of RAD202 and generating meaningful data that could
support a differentiated radiotherapeutic option for HER2-positive patients in need of new
treatment alternatives.”
The Phase 1 ‘HEAT’ study is currently being conducted at clinical centers across Australia. The
announcement of the previous dose level in this study of 130mCi was released on 8 April 2026.
About 177Lu-RAD202:
RAD202 is a proprietary single-domain monoclonal antibody (sdAb) that targets the Human
Epidermal Growth Factor Receptor 2 (HER2)-positive expression in advanced solid tumors. HER2 is
overexpressed in breast cancer and several other solid tumors and represents a validated target in
oncology. In a previous diagnostic study of ten HER2-positive breast cancer patients, RAD202
demonstrated clinical proof-of-concept and had positive safety and biodistribution.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
1
clinicaltrials.gov/study/NCT06824155
ASX ANNOUNCEMENT
August 20, 2026
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
company has a pipeline of distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes
one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate
and brain. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Share your feedback
Discover